Anavex Lf SC Cmn (AVXL) 3.21 $AVXL Technical Roundup on

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Anavex Lf SC Cmn (AVXL) 3.21 $AVXL

Technical Roundup on Biotech Stocks -- Anavex Life Sciences, Threshold Pharma, StemCells, and Aratana Therapeutics
PR Newswire - Wed Aug 17, 7:17AM CDT
Biotechnology is a risk-taking arena where investors either come out a winner or the other way around. The industry is involved in drug development and clinical researches that are intended to treat and cure various medical conditions. Stock-Callers.com takes a look at these equities and see how they performed at the closing bell on Tuesday, August 16, 2016: Anavex Life Sciences Corp. (NASDAQ: AVXL), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), StemCells Inc. (NASDAQ: STEM), and Aratana Therapeutics Inc. (NASDAQ: PETX). Access these companies' trade alerts for free by signing up now at: Sign up today and download for free the research reports for the stocks covered today at: http://stock-callers.com/registration
AVXL: 3.21 (-0.11), STEM: 1.24 (-0.42), PETX: 9.11 (+0.06), THLD: 0.87 (+0.09)

Anavex Reports Fiscal Third Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 11, 3:15PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and nine months ended June 30, 2016.
AVXL: 3.21 (-0.11)

Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients Presented at AAIC 2016
GlobeNewswire - Fri Jul 29, 8:20AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), confirms the information in the July 27, 2016 press release announcing positive results from the Phase 2a Alzheimer's trial for ANAVEX 2-73.
AVXL: 3.21 (-0.11)

Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016
GlobeNewswire - Wed Jul 27, 12:00PM CDT
Sustained Response Through 31 Weeks for both Cognitive (MMSE) and Functional (ADCS-ADL) Measures
AVXL: 3.21 (-0.11)

Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 3.21 (-0.11), ANIP: 67.99 (-1.00), RTRX: 16.79 (-0.24), ACOR: 24.85 (-0.15)

Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms
GlobeNewswire - Wed Jun 22, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration's Office of Orphan Product Development has granted Orphan Drug Designation to ANAVEX 2-73 for the treatment of infantile spasms.
AVXL: 3.21 (-0.11)

Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 16.24 (+0.08), PACB: 8.88 (-0.23), AVXL: 3.21 (-0.11), PPHM: 0.36 (-0.01)

Market Has Not Yet Noticed Potential in Anavex Life Sciences (AVXL); Have You?
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 7:48AM CDT
Anavex Life Sciences is seeing solid earnings estimate revisions and has an impressive Zacks Rank but that is not yet reflected in its price
AVXL: 3.21 (-0.11)

Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X - Autism-Related Disorders
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive data of ANAVEX 2-73 in an exploratory study in a Fragile X syndrome model presented at the Gordon Research Conference for Fragile X and Autism-Related Disorders, being held June 5-10, 2016 in Mount Snow, VT.
AVXL: 3.21 (-0.11)

Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome
GlobeNewswire - Fri May 20, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration's (FDA) Office of Orphan Product Development (OOPD) has granted Orphan Drug Designation (ODD) to ANAVEX 2-73 for the treatment of Rett syndrome.
AVXL: 3.21 (-0.11)

Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms
GlobeNewswire - Wed May 18, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces today that treatment with ANAVEX 2-73 significantly reduced the number of spasms in an animal model with infantile spasms (epileptic spasms) in infant rats.
AVXL: 3.21 (-0.11)

Anavex Life Sciences reports 2Q loss
Automated Insights - Wed May 11, 6:15AM CDT
NEW YORK (AP) _ Anavex Life Sciences Corp. (AVXL) on Wednesday reported a loss of $2 million in its fiscal second quarter.
AVXL: 3.21 (-0.11)

Anavex Reports Fiscal Second Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and six months ended March 31, 2016.
AVXL: 3.21 (-0.11)

Could a Pill to Cure Alzheimer's Disease Become Available Soon?
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 26, 3:22PM CDT
Image source: Anavex Life Sciences. Recently, two women in Melbourne with Alzheimer's disease found themselves able to complete complex tasks they haven't been capable of for some time. One woman found herself suddenly able to play the piano again,...
AVXL: 3.21 (-0.11)

4 Stocks That Are Making Huge Gains Today
ACCESSWIRE - Mon Apr 25, 9:45AM CDT
NEW YORK, NY / ACCESSWIRE / April 25, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Friday. TPUB, AVXL, NEOT and LGCY are on high breakout alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
LGCY: 1.66 (-0.02), TPUB: 13.96 (+0.17), AVXL: 3.21 (-0.11), NEOT: 0.87 (unch)

U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia
GlobeNewswire - Fri Apr 08, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ANAVEX 3-71 for the treatment of Frontotemporal dementia (FTD).
AVXL: 3.21 (-0.11)

Anavex Presents New Data on Preclinical Development of ANAVEX 3-71
GlobeNewswire - Mon Mar 14, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive preclinical data on sigma-1 agonist ANAVEX 3-71 (formerly AF710B). The results show a statistically significant reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71.
AVXL: 3.21 (-0.11)

Covered Call Alerts For Celldex Therapeutics, Anavex Life Sciences Corp, El Pollo Loco, First Solar, Dollar Tree and hundreds of other stocks Released By InvestorsObserver
PR Newswire - Fri Mar 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for CLDX, AVXL, LOCO, FSLR and DLTR.
FSLR: 37.80 (+0.28), DLTR: 95.57 (-0.29), AVXL: 3.21 (-0.11), CLDX: 3.95 (-0.21), LOCO: 13.79 (+0.17), WTW: 11.19 (+0.15)

IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Anavex Life Sciences Corp. and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm
BusinessWire - Wed Feb 10, 3:26PM CST
Lundin Law PC announces a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company" (NASDAQ: AVXL) concerning possible violations of federal securities laws between May 17, 2013 and December 28, 2015. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the February 29, 2016, lead plaintiff motion deadline.
AVXL: 3.21 (-0.11)

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Anavex Life Sciences Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of February 29, 2016
BusinessWire - Wed Feb 10, 12:37PM CST
The following statement is being issued by Levi & Korsinsky, LLP:
AVXL: 3.21 (-0.11)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 120

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines

Updated Category News Views 105

Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...

Continue Reading
MFB Bancorp Offering Puts Chicago Bank Conversion First

Updated Category News Views 70

A small Chicago thrift is asking investors to fund a corporate makeover, and the fine print matters more than the $10 sticker price. MFB Bancorp has commenced an offering tied to the planned conversion of Mutual Federal Bancorp, MHC from a mutual holding company structure into a stock holding company. This is not some high-growth bank story with a shiny new branch map. It...

Continue Reading
Alphabet Lawsuit Puts Gemini Delays Under a Microscope

Updated Category News Views 173

July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 119

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading
Minno Bets on Listener Kids to Build Premium Growth

Updated Category News Views 131

Children’s media rarely gets a clean strategic move, but this one comes pretty close. Minno has signed a worldwide, multi-year agreement making it the exclusive faith-based streaming home for Listener Kids’ video library, while commissioning 66 new episodes for its own service. For a company trying to build a serious Christian family-media business, that is more than...

Continue Reading
Qiandaohu Whisky Film Puts Craft Before Market Hype

Updated Category News Views 80

Three Distillers, One Very Large Question Whisky does not become world-class because a camera crew found a pretty shoreline. That is the blunt truth sitting underneath this Nov. 19, 2026 documentary release from CCTV+. The film follows three international distillers working at three separate whisky distilleries along Qiandaohu, while also lingering on their day-to-day...

Continue Reading
EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 111

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading
Titan Center Lease Gives Pocatello Retail Some Teeth

Updated Category News Views 157

A chicken sandwich lease is not usually a redevelopment thesis, yet Titan Center's new Chick-fil-A deal carries more weight than a routine restaurant announcement. Industrial Realty Group has landed a nationally recognized tenant at the entrance to a property with a long, complicated industrial past. In a smaller market, that sort of win can matter. Retail momentum is...

Continue Reading

Top 5 Most Recently Viewed Articles

Curis Advances CLL Treatment With Promising Start

Updated Category News Views 76

You know, every now and then, a glimmer of potential bites back against the usual cancer battle headlines. Today, Curis, Inc. (NASDAQ: CRIS) is that flickering hope in the often murky world of biotech, making moves to stir things up with its TakeAim CLL study. Let's do a deep dive into exactly what this could mean for the world battling chronic lymphocytic leukemia....

Continue Reading
Robust Growth Expected in Antimicrobial Coatings Market

Updated Category News Views 243

Antimicrobial Coating Market Predicted to Surge The Global antimicrobial coating market is on track for remarkable growth, projected to reach US$ 8.82 billion by 2031 from US$ 3.78 billion in 2023. This substantial growth corresponds to a compound annual growth rate (CAGR) of 11.2% throughout the forecast period. Growing Demand for Antimicrobial Coatings One of the...

Continue Reading
Royal Unibrew A/S Transactions Report by Management Personnel

Updated Category News Views 121

Recent Transactions by Management at Royal Unibrew A/S Royal Unibrew A/S, a prominent player in the beverage industry, has recently made important disclosures regarding share transactions executed by its key management personnel. This announcement is made in accordance with the regulations aimed at promoting transparency in the market. Transaction Details Overview This...

Continue Reading
Innovative Support Post Enhances Horse Racing Safety Measures

Updated Category News Views 124

Innovative Design for Racing Safety Recently, a creative inventor conceptualized an advanced support post specifically for horse racing track railings. This inventive solution was born from a desire to lessen the risk of injury to jockeys and horses. The inventor aimed to create a product that enhances safety on race tracks while providing peace of mind for everyone...

Continue Reading
Aurigo Software Partners with Philadelphia for Infrastructure Growth

Updated Category News Views 258

Aurigo Software Partners with Philadelphia for Infrastructure Growth Aurigo Software, known for its expertise in capital planning and construction management, has announced a significant partnership with the City of Philadelphia. This multiyear contract aims to leverage Aurigo's leading product suite, Masterworks, to improve infrastructure program management for the city....

Continue Reading